Zelboraf

Under the trade name of Zelboraf, Vemurafenib was developed by the company Plexxikon and is now being marketed by the pharmaceutical company Hoffman La Roche. The drug, which is used to treat metastatic melanoma in patients, is functionally a BRAF inhibitor and is one of the very few of its kind. BRAF is fundamentally a gene that is involved in the synthesis of the B-RAF proteins. The B-RAF proteins are further implicated with the signaling process in the cells and thus promote cellular growth. Any mutations –that may be inherited or acquired – in the BRAF gene can bring forth the onset of cancer in the body. So, Vemurafenib is the drug that is intended to be used in order to inhibit the actions of the mutated gene and thus bring the abnormal growth of tumor cells to a halt.

However, Zelboraf might not be the appropriate drug for the treatment of melanoma for all patients. In such circumstances, its alternatives would be looked for rather than the drug itself. Illustrating such a situation would be the patients with melanoma unassociated with wild/mutated type BRAF, who necessitate alternative treatmental options rather than Vemurafenib. Nonetheless, prior to purchasing the drug, enough Zelboraf purchasing information is essentially required. Isrameds is one of the most accredited zelboraf pharmacies to get the purchasing information from.